Join the Oncology Voice Network. Join for Free
Objection Handling for Field Medical Professionals
MSL objection handling 5 e's framework medical science liaisons pre-call planning negotiation tactics

Objection Handling for Field Medical Professionals


Share This Article


Summary

In this episode, Linda Traylor joins Tom Caravela to delve into the art of objection handling for MSLs. They explore the nuances between MSLs and sales teams, introducing a structured approach known as the 5 e's framework. Emphasizing the significance of pre-call planning, the discussion highlights common pitfalls and strategies to prepare for frequent objections. The conversation underscores the value of team practice and the influence of MSL opinions, while stressing mentorship and collaboration. The episode wraps up with a teaser for an upcoming book review on negotiation tactics, inviting listeners to engage and apply these insights.

My guest today is Linda Traylor, Sr Principal Medical Affairs at IQVIA and we discuss objection handling for MSLs and field medical professionals.

Linda shares…

👉 How objection handling for MSLs is different than objection handling for sales reps
👉 The framework MSLs should use for objection handling
👉 What mistakes MSLs make in handling objections
👉 If MSLs should address and handle every objection
👉 The importance of preparation and pre-call planning
👉 Typical examples of objections from KOLs

Click for Source
MSL objection handling, 5 e's framework, medical science liaisons, pre-call planning, negotiation tactics

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN